Pharmacokinetics
SECONDARY
Another secondary objective in this study was to characterize the pharmacokinetic profile of divarasib plus cetuximab. We previously reported that the mean half-life of a single dose of divarasib 400 mg administered as a single agent was 17.6 ± 2.7 h and the corresponding accumulation index after daily dosing to steady state (area under the concentration–time curve from 0 to 24 h (R